Publications by authors named "G Biondi Zoccai"

Introduction: In patients with chronic coronary syndromes (CCS), the benefit of percutaneous coronary intervention (PCI) added to optimal medical therapy (OMT) remains unclear. The indication to PCI may be driven either by angiographic evaluation or ischemia assessment, thus depicting different potential strategies which have not yet been thoroughly compared.

Methods: Randomized controlled trials (RCTs) comparing OMT versus PCI angio-guided or versus PCI non-invasive or invasive ischemia guided were identified and compared via network meta-analysis.

View Article and Find Full Text PDF

Background: Drug-coated balloons (DCB) are emerging as an alternative to permanent implants for managing de novo coronary artery disease, particularly in small vessels (SVD). This sub-analysis of the PICCOLETO II study aimed to compare the performance of DCB and DES in terms of Murray's law-based quantitative flow ratio (μFR) changes between baseline, post-percutaneous coronary intervention (PCI), and follow-up.

Methods: Patients with a clinical indication for PCI were assigned to receive either Xience DES or Elutax SV/Emperor DCB.

View Article and Find Full Text PDF
Article Synopsis
  • Platelets have a significant impact on aortic stenosis (AS) and patients undergoing transcatheter aortic valve implantation (TAVI), prompting an analysis of their indices in relation to AS stages.
  • In a study involving 220 TAVI patients, they were categorized into 5 AS stages based on cardiac damage, revealing a correlation between higher mean platelet volume (MPV) and advanced AS staging, as well as lower hemoglobin levels.
  • The findings indicate that while MPV and immature platelet fraction (IPF) show variations across stages, only MPV and body mass index (BMI) were significant predictors of higher AS staging in the logistic regression analysis.
View Article and Find Full Text PDF
Article Synopsis
  • - The study investigates the relationship between peak high-sensitivity cardiac troponin (hs-cTn) levels and one-year mortality in patients admitted to intensive cardiovascular care units (ICCU) from 2019 to 2023.
  • - A total of 4149 patients were analyzed, revealing that those with hs-cTnI levels ≥100,000 ng/L had a significantly higher risk of mortality compared to lower levels, particularly in non-ST elevation myocardial infarction (NSTEMI) cases.
  • - The findings suggest that while high hs-cTnI levels indicate poor prognosis, the impact on mortality rates varies notably between patients with ST elevation myocardial infarction (STEMI) and NSTEMI, indicating a need
View Article and Find Full Text PDF

Heart failure with reduced ejection fraction (HFrEF) represents an emerging epidemic, particularly affecting frail, older, and multimorbid patients. Current therapy for the management of HFrEF includes four different classes of disease-modifying drugs, commonly referred to as 'four pillars', which target the neurohormonal system that is overactivated in HF and contributes to its progression. These classes of drugs include β-blockers, inhibitors of the renin-angiotensin-aldosterone system, mineralocorticoid receptor antagonists, and sodium-glucose co-transporter-2 (SGLT2) inhibitors.

View Article and Find Full Text PDF